Allogene Therapeutics
Allogene Therapeutics
ALLO
NASDAQ
1.88
USD
-8.74%
About
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma.
It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies.
It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.8M |
| Three Month Average Volume | 54.1M |
| High Low | |
| Fifty-Two Week High | 5.775 USD |
| Fifty-Two Week Low | 2.01 USD |
| Fifty-Two Week High Date | 08 Mar 2024 |
| Fifty-Two Week Low Date | 05 Jul 2024 |
| Price and Volume | |
| Current Price | 2.63 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.13% |
| Thirteen Week Relative Price Change | -1.71% |
| Twenty-Six Week Relative Price Change | -51.58% |
| Fifty-Two Week Relative Price Change | -46.04% |
| Year-to-Date Relative Price Change | -30.81% |
| Price Change | |
| One Day Price Change | -1.13% |
| Thirteen Week Price Change | 5.20% |
| Twenty-Six Week Price Change | -46.76% |
| Five Day Price Change | 0.77% |
| Fifty-Two Week Price Change | -32.39% |
| Year-to-Date Price Change | -18.07% |
| Month-to-Date Price Change | -10.54% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.03739 USD |
| Book Value Per Share (Most Recent Quarter) | 2.46371 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.03739 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.46371 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.50091 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00061 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00038 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.0854 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.58767 USD |
| Normalized (Last Fiscal Year) | -2.001 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.0854 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.58767 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.0854 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.58767 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.66064 USD |
| Cash Per Share (Most Recent Quarter) | 2.1269 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.99491 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.55132 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.33926 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -910 |
| Cash Flow Revenue (Trailing Twelve Months) | -352,192 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -429,881.50% |
| Pretax Margin (Last Fiscal Year) | -344,489.50% |
| Pretax Margin (5 Year) | -1,123.73% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -344,986.30% |
| Operating Margin (Trailing Twelve Months) | -444,676.90% |
| Operating Margin (5 Year) | -1,140.21% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -344,489.50% |
| Net Profit Margin (Trailing Twelve Months) | -429,881.50% |
| Net Profit Margin (5 Year) | -1,123.44% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -12.10% |
| Tangible Book Value (5 Year) | -6.12% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 6.56% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -14.06% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 35.30% |
| EPS Change (Trailing Twelve Months) | 37.07% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -444,628,000 |
| Net Debt (Last Fiscal Year) | -448,697,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5.8K |
| Price to Sales (Trailing Twelve Months) | 8.5K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 12 |
| Current Ratio (Most Recent Quarter) | 12 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -239,249,000 |
| Free Cash Flow (Trailing Twelve Months) | -228,925,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -44.70% |
| Return on Assets (Trailing Twelve Months) | -39.41% |
| Return on Assets (5 Year) | -28.46% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -55.51% |
| Return on Equity (Trailing Twelve Months) | -49.11% |
| Return on Equity (5 Year) | -32.94% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -47.65% |
| Return on Investment (Trailing Twelve Months) | -42.15% |
| Return on Investment (5 Year) | -30.21% |